Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

MiNK Therapeutics, Inc. - Common Stock (NQ:INKT)

11.05 +0.08 (+0.69%)
Streaming Delayed Price Updated: 2:26 PM EST, Feb 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about MiNK Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone Symposia
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics and University of Wisconsin–Madison Announce Phase 1 Clinical Trial of Allo-iNKT Cell Therapy (AgenT-797) to Evaluate Prevention of Graft-Versus-Host Disease
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics Announces New Data Showing MiNK-215 Drives Potent Anti-Tumor Activity in Treatment-resistant Solid Tumors
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics Reports Q3 2025 Results and Accelerates iNKT Platform Toward Pivotal Development Across Oncology, Pulmonary Disease, and Transplantation
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors at SITC 2025
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics to Report Third Quarter 2025 Financial Results and Highlight Clinical and Corporate Milestones Advancing iNKT Platform Toward Pivotal Development
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics to Present Late-Breaking Data on AgenT-797 in Solid Tumors at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics Appoints Colonel (Ret.) John B. Holcomb, MD, to Board of Directors
Strengthening Leadership to Accelerate iNKT Therapies into Immune-Mediated Disease, Pulmonary Disorders, and Global Health Security 
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics Dr. Jennifer Buell to Deliver Featured Plenary at 10th Annual CAR-TCR Summit in Boston, MA
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics Appoints Dr. Terese C. Hammond to Accelerate iNKT Pipeline to Pivotal Development
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 Results
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics Announces Frontiers in Immunology Publication Highlighting iNKT Cells as a Dual-Function Platform Key to Overcoming Barriers in Solid Tumor Cell Therapy
iNKT cells uniquely remodel the tumor microenvironment, overcome immune resistance, and enable scalable off-the-shelf cell therapy 
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics Announces Publication of Complete Remission Following Allogeneic iNKT Cell Therapy in Metastatic Testicular Cancer
New report adds to growing evidence of iNKT cell therapy’s potential in solid tumors 
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics Announces Virtual Annual Shareholders Meeting
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics Awarded Prestigious NIAID Grant to Advance Allo-iNKT Cell Therapy for Prevention of GvHD in Stem Cell Transplant Patients
Non-dilutive NIH funding supports development of MiNK’s allogeneic iNKT platform for immune regulation in high-risk HSCT settings 
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics Reports Q1 2025 Results and Highlights Clinical & Strategic Progress
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics Presents First-in-Kind Allo-iNKTs Combination Data in 2L Gastric Cancer at AACR IO Annual Meeting
Addition of AgenT-797 with Checkpoint Inhibitors, BOT/BAL, and Chemotherapy Demonstrates Robust Immune Activation, Offering Potential to Overcome Refractory Gastric Cancers 
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics Regains Full Compliance with Nasdaq Listing Requirements
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics to Present iNKT Cell Therapy in Gastric Cancer at ASCO GI Annual Meeting
Presentation will feature the ongoing Phase 2 study of agenT-797 in refractory gastric cancer 
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics Reports Third Quarter 2024 Results and Business Update
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics to Provide Corporate Update and Third Quarter 2024 Financial Report
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK’s iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid Cancers at SITC 2024
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics Announces Appointment of Dr. Robert Kadlec to Board of Directors
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics and Autonomous Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors
From MiNK Therapeutics
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.